Trial reportAesthetic plastic surgery2025
Efficacy and Safety of Collagen Filler for Intradermal Injection: A Randomized Prospective Controlled Multicenter Study.
Trial report in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial.Journal of cosmetic dermatology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the increasing demand for minimally invasive aesthetic procedures, intradermal injection has emerged as a promising method to improve skin condition. However, there is a lack of robust clinical evidence supporting the efficacy and safety of intradermal collagen injections.
objectiveThe purpose of this study is to investigate the improvement of facial skin and safety of collagen intradermal injections.
methodsThis prospective, multicenter, randomized, assessor-masked clinical trial enrolled 480 subjects aged 18-65 seeking facial skin enhancement. Subjects were randomized into treatment (n = 240) and control (n = 240) groups. The treatment group received three sessions of intradermal collagen injections at four-week intervals. Assessments included the Global Aesthetic Improvement Scale (GAIS), composite scale for skin dryness and dull complexion, Allergan Fine Lines Scale (AFLS), Allergan Skin Roughness Scale (ASRS), skin hydration, elasticity, and safety evaluations.
resultsThe GAIS and skin improvement rates showed significant differences between groups (P < 0.0001), with the treatment group demonstrating superior efficacy. No significant differences were observed in skin hydration and elasticity (P > 0.05). The treatment group exhibited higher improvement rates in GAIS, dull complexion, fine lines, and skin roughness at 4 weeks post-final injection compared to the control group. No severe treatment-emergent adverse events related to the trial device occurred.
conclusionIntradermal collagen injections significantly enhance skin texture and demonstrate safety and reliability in clinical settings, offering a favorable risk-benefit ratio for appropriate candidates. LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
40425884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.